Risk Assessment Report – 29 july 2020
Risk Assessment Report – 29 july 2020
Rapid Risk Assessment
July 29, 2020
Risk Assessment Report – 29 july 2020
Time Period Covered July 29, 2020 - July 29, 2020
- Worldwide, there have been over 16.7 million reported cases, and more than 660,000 deaths attributed to COVID-19. Globally, many countries are seeing a second rise in case numbers. In North America, the resurgence of infections was seen in recent weeks, mostly driven by new outbreaks in the US. In Europe, Spain’s resurgence in cases has sparked fears of a more widespread rise in cases. In Asia, Japan’s capital, Tokyo is driving a second increase in cases nationwide. In Latin America and Africa, cases continue to rise as South Africa, Egypt, and Brazil remain the largest regional hotspots.
- Six vaccine candidates have entered Phase 3 and Phase 2/3 combined clinical trials, involving large-scale efficacy tests. In the United States, the phase 3 mRNA-1273 study is targeting 30,000 healthy volunteers across 89 sites in the US. The BNT162b2 candidate in Phase 2/3 is recruiting 30,000 healthy volunteers from the US, Argentina, Brazil, and Germany. Two inactivated vaccine candidates developed in China are undergoing studies in Brazil and the United Arab Emirates, with an estimated recruitment number of around 10,000. In the UK, the AZD1222 candidate is now in Phase 2/3 in England and Phase 3 in Brazil and South Africa. Study locations were chosen on the basis of there being large ongoing outbreaks with the consequent potential ability to determine a significant protective effect of the vaccine candidate under trial within a suitable timeframe. In Australia, the live-attenuated BCG vaccine previously approved for tuberculosis is now under Phase 3 trial for COVID-19, with estimated recruitment of 10,000 healthcare workers in Australia
Risk Assessment Report – 29 july 2020